Revealing the Drug-Resistant Mechanism for Diarylpyrimidine Analogue Inhibitors of HIV-1 Reverse Transcriptase

Chemical Biology and Drug Design

Volumn 78, Issue 3, 2011, Pages 427-437

  Zhang, Hao ^a   Qin, Fang ^a   Ye, Wei ^a   Li, Zeng ^a   Ma, Songyao ^a   Xia, Yan ^a   Jiang, Yi ^a   Zhu, Jiayi ^b   Li, Yixue ^c   Zhang, Jian ^b   Chen, Hai Feng ^a,c  

^a Shanghai Jiao Tong University   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

Author keywords

3D QSAR; Diarylpyrimidine analogues; Drug resistance; HIV 1 reverse transcriptase; Molecular dynamics simulation

Indexed keywords

DIARYLPYRIMIDINE ANALOG; DIARYLTRIAZINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; DRUG BINDING; DRUG MECHANISM; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SIMULATION; THREE DIMENSIONAL IMAGING; VIRUS MUTANT; WILD TYPE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTATION; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80051594199     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01163.x     Document Type: Article

References (62)

1. Broder S. (2010) The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res;85:1-18.
2. Sarafianos S.G., Marchand B., Das K., Himmel D.M., Parniak M.A., Hughes S.H., Arnold E. (2009) Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol;385:693-713.
3. Maeda K., Mitsuya H. (2007) Development of therapeutics for AIDS: structure-based molecular targeting. Tuberculosis (Edinb);87(Suppl 1):S31-S34.
4. de Bethune M.P. (2009) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20years (1989-2009). Antiviral Res;85:75-90.
5. Cahn P., Wainberg M.A. (2010) Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine. J Antimicrob Chemother;65:213-217.
6. Cihlar T., Laflamme G., Fisher R., Carey A.C., Vela J.E., Mackman R., Ray A.S. (2009) Novel nucleotide human immunodeficiency virus reverse transcriptase inhibitor GS-9148 with a low nephrotoxic potential: characterization of renal transport and accumulation. Antimicrob Agents Chemother;53:150-156.
7. Cihlar T., Ray A.S. (2010) Nucleoside and nucleotide HIV reverse transcriptase inhibitors: 25years after zidovudine. Antiviral Res;85:39-58.
8. Su D.S., Lim J.J., Tinney E., Wan B.L., Young M.B., Anderson K.D., Rudd D. et al. (2009) Biaryl ethers as novel non-nucleoside reverse transcriptase inhibitors with improved potency against key mutant viruses. J Med Chem;52:7163-7169.
9. Spallarossa A., Cesarini S., Ranise A., Bruno O., Schenone S., La Colla P., Collu G., Sanna G., Secci B., Loddo R. (2009) Novel modifications in the series of O-(2-phthalimidoethyl)-N-substituted thiocarbamates and their ring-opened congeners as non-nucleoside HIV-1 reverse transcriptase inhibitors. Eur J Med Chem;44:1650-1663.
10. Piscitelli F., Coluccia A., Brancale A., La Regina G., Sansone A., Giordano C., Balzarini J., Maga G., Zanoli S., Samuele A., Cirilli R., La Torre F., Lavecchia A., Novellino E., Silvestri R. (2009) Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. J Med Chem;52:1922-1934.
11. Nichols S.E., Domaoal R.A., Thakur V.V., Tirado-Rives J., Anderson K.S., Jorgensen W.L. (2009) Discovery of wild-type and Y181C mutant non-nucleoside HIV-1 reverse transcriptase inhibitors using virtual screening with multiple protein structures. J Chem Inf Model;49:1272-1279.
12. Le Van K., Cauvin C., de Walque S., Georges B., Boland S., Martinelli V., Demonte D., Durant F., Hevesi L., Van Lint C. (2009) New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. J Med Chem;52:3636-3643.
13. Jones L.H., Allan G., Barba O., Burt C., Corbau R., Dupont T., Knochel T. et al. (2009) Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. J Med Chem;52:1219-1223.
14. Tucker T.J., Sisko J.T., Tynebor R.M., Williams T.M., Felock P.J., Flynn J.A., Lai M.T. et al. (2008) Discovery of 3-{5-[(6-amino-1H-pyrazolo[3, 4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5 -chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses. J Med Chem;51:6503-6511.
15. Ren J., Chamberlain P.P., Stamp A., Short S.A., Weaver K.L., Romines K.R., Hazen R., Freeman A., Ferris R.G., Andrews C.W., Boone L., Chan J.H., Stammers D.K. (2008) Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. J Med Chem;51:5000-5008.
16. Das K., Bauman J.D., Clark A.D. Jr, Frenkel Y.V., Lewi P.J., Shatkin A.J., Hughes S.H., Arnold E. (2008) High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutations. Proc Natl Acad Sci U S A;105:1466-1471.
17. Lewis W., Day B.J., Copeland W.C. (2003) Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov;2:812-822.
18. Ludovici D.W., De Corte B.L., Kukla M.J., Ye H., Ho C.Y., Lichtenstein M.A., Kavash R.W. et al. (2001) Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues. Bioorg Med Chem Lett;11:2235-2239.
19. Ghosn J., Chaix M.L., Delaugerre C. (2009) HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev;11:165-173.
20. Mackman R.L., Zhang L., Prasad V., Boojamra C.G., Douglas J., Grant D., Hui H., Kim C.U., Laflamme G., Parrish J., Stoycheva A.D., Swaminathan S., Wang K., Cihlar T. (2007) Synthesis, anti-HIV activity, and resistance profile of thymidine phosphonomethoxy nucleosides and their bis-isopropyloxymethylcarbonyl (bisPOC) prodrugs. Bioorg Med Chem;15:5519-5528.
21. Chen H.F. (2008) Mechanism of coupled folding and binding in the siRNA-PAZ complex. J Chem Theory Comput;4:1360-1368.
22. Clavel F., Hance A.J. (2004) HIV drug resistance. N Engl J Med;350:1023-1035.
23. Udier-Blagovic M., Watkins E.K., Tirado-Rives J., Jorgensen W.L. (2003) Activity predictions for efavirenz analogues with the K103N mutant of HIV reverse transcriptase. Bioorg Med Chem Lett;13:3337-3340.
24. Li Z., Han J., Chen H.F. (2008) Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor. Chem Biol Drug Des;72:350-359.
25. Li Z., Zhang H., Li Y., Zhang J., Chen H.-F. (2011) Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR. Chem Biol Drug Des;77:63-74.
26. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. (1988) Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods;20:309-321.
27. Das K., Clark A.D., Lewi P.J., Heeres J., de Jonge M.R., Koymans L.M.H., Vinkers H.M. et al. (2004) Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem;47:2550-2560.
28. Ren J., Nichols C.E., Chamberlain P.P., Weaver K.L., Short S.A., Stammers D.K. (2004) Crystal structures of HIV-1 reverse transcriptases mutated at Codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J Mol Biol;336:569-578.
29. Lindberg J., Sigurdsson S., Lowgren S., Andersson H.O., Sahlberg C., Noreen R., Fridborg K., Zhang H., Unge T. (2002) Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. Eur J Biochem;269:1670-1677.
30. Ren J., Nichols C., Bird L., Chamberlain P., Weaver K., Short S., Stuart D.I., Stammers D.K. (2001) Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. J Mol Biol;312:795-805.
31. Hsiou Y., Das K.Y., Ding J.P., Clark A.D., Kleim J.P., Rosner M., Winkler I., Riess G., Hughes S.H., Arnold E. (1998) Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. J Mol Biol;284:313-323.
32. Clark M., Cramer R.D. III, Opdenbosch N.V. (1989) Validation of the general purpose tripos 5.2 force field. J Comput Chem;10:982-1012.
33. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem;19:1639-1662.
34. Cramer R.D. III, Patterson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA) 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc;110:5959-5967.
35. Bastien P., Vinzi V.E., Tenenhaus M. (2005) PLS generalised linear regression. Comput Stat Data Anal;48:17-46.
36. Klebe G., Abraham U., Mietzner T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem;37:4130-4146.
37. Bohm M., Sturzebecher J., Klebe G. (1999) Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem;42:458-477.
38. Case D.A., Pearlman D.A., Caldwell J.W., Cheatham T.E. III, Wang J., Ross W.S., Simmerling C.L. et al. (2004) AMBER 8. San Francisco: University of California.
39. Cieplak P., Caldwell J., Kollman P. (2001) Molecular mechanical models for organic and biological systems going beyond the atom centered two body additive approximation: aqueous solution free energies of methanol and N-methyl acetamide, nucleic acid base, and amide hydrogen bonding and chloroform/water partition coefficients of the nucleic acid bases. J Comput Chem;22:1048-1057.
40. Jakalian A., Jack D.B., Bayly C.I. (2002) Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation. J Comput Chem;23:1623-1641.
41. Ryckaert J.P., Arialdi G., Melchionna S. (2001) Molecular dynamics of polymers with explicit but frozen hydrogens. Mol Phys;99:155-165.
42. Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys;79:926-935.
43. Darden T., York D., Pedersen L. (1993) Particle mesh Ewald: an N [center-dot] log(N) method for Ewald sums in large systems. J Chem Phys;98:10089-10092.
44. Chen H.F. (2009) Aggregation mechanism investigation of the GIFQINS cross-beta amyloid fibril. Comput Biol Chem;33:41-45.
45. Chen H.F. (2009) Molecular dynamics simulation of phosphorylated KID post-translational modification. PLoS ONE;4:e6516.
46. Chen H.F., Luo R. (2007) Binding induced folding in p53-MDM2 complex. J Am Chem Soc;129:2930-2937.
47. Chen Y., He Y.J., Wu M., Yan G., Li Y., Zhang J., Chen H.F. (2010) Insight into the stability of cross-beta amyloid fibril from molecular dynamics simulation. Biopolymers;93:578-586.
48. Qin F., Chen Y., Li Y.X., Chen H.F. (2009) Induced fit of mRNA-TIS11D Complex. J Chem Phys;131:115103.
49. Qin F., Chen Y., Wu M., Li Y., Zhang J., Chen H.F. (2010) Induced fit or conformational selection for RNA/U1A folding. RNA;16:1053-1061.
50. Chen H.F., Yao X.J., Li Q., Yuan S.G., Panaye A., Doucet J.P., Fan B.T. (2003) Comparative study of non nucleoside inhibitors with HIV-1 reverse transcriptase based on 3D-QSAR and docking. SAR QSAR Environ Res;14:455-474.
51. Hu R., Barbault F., Delamar M., Zhang R. (2009) Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem;17:2400-2409.
52. Ragno R., Mai A., Sbardella G., Artico M., Massa S., Musiu C., Mura M., Marturana F., Cadeddu A., La Colla P. (2004) Computer-aided design, synthesis, and anti-HIV-1 activity in vitro of 2-alkylamino-6-[1-(2, 6-difluorophenyl)alkyl]-3, 4-dihydro-5-alkylpyrimidin- 4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. J Med Chem;47:928-934.
53. Chen H.F., Fan B.T., Zhao C.Y., Xie L., Zhao C.H., Zhou T., Lee K.H., Allaway G. (2005) Computational studies and drug design for HIV-1 reverse transcriptase inhibitors of 3', 4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (DCK) analogs. J Comput Aided Mol Des;19:243-258.
54. Hsiou Y., Ding J.P., Das K., Clark A.D., Boyer P.L., Lewi P., Janssen P.A.J., Kleim J.P., Rosner M., Hughes S.H., Arnold E. (2001) The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol;309:437-445.
55. Barreca M.L., Rao A., De Luca L., Iraci N., Monforte A.M., Maga G., De Clercq E. (2007) Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains. Bioorg Med Chem Lett;17:1956-1960.
56. Deeks S.G. (2001) International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr;26(Suppl 1):S25-S33.
57. Li Z., Zhang H., Li Y., Zhang J., Chen H.-F. (2011) Drug resistant mechanism of diaryltriazine analog inhibitors of HIV-1 reverse transcriptase using molecular dynamics simulation and 3D-QSAR. Chem Biol Drug Des;77:63-74.
58. Rodriguez-Barrios F., Balzarini J., Gago F. (2005) The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. J Am Chem Soc;127:7570-7578.
59. Rodriguez-Barrios F., Gago F. (2004) Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. J Am Chem Soc;126:15386-15387.
60. Alzate-Morales J.H., Vergara-Jaque A., Caballero J. (2010) Computational study on the interaction of N1 substituted pyrazole derivatives with B-raf kinase: an unusual water wire hydrogen-bond network and novel interactions at the entrance of the active site. J Chem Inf Model;50:1101-1112.
61. Sotriffer C.A., Ni H., McCammon J.A. (2000) HIV-1 integrase inhibitor interactions at the active site: prediction of binding modes unaffected by crystal packing. J Am Chem Soc;122:6136-6137.
62. Liang Y.H., Chen F.E. (2009) QSAR studies for diarylpyrimidines against HIV-1 reverse transcriptase wild-type and mutant strains. Eur J Med Chem;44:625-631.